BIOGRAPHICAL SKETCH

NAME	POSITION TITLE
James M. Ford, M.D.	Associate Professor of Medicine, Pediatrics and Genetics
eRA COMMONS USER NAME	
FORD.JAMES	

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)*

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
Yale University	B.A.	1984	Biology
Yale University School of Medicine	M.D.	1989	Medicine
Stanford University School of Medicine	Fellow	1994	Medical Oncology
Stanford University	Postdoc	1997	Biological Sciences

A. Personal Statement

My overall research goals are to understand the role of genetic changes in cancer genes in the risk and development of solid tumors. My laboratory research focuses on how DNA repair and DNA damage response pathways are critical to tumorigenesis and are potential candidates for targeted therapeutics and prevention. A major focus of our current work is the characterization of DNA repair defects in solid tumors, and the synergistic activity of DNA damaging chemotherapy drugs and radiation with PARP inhibitors in basal-like breast cancer and GI cancers. We are highly engaged in the translation of these ideas to the clinic through clinical trials in patients with high genetic risk for cancer. I also direct the Stanford Cancer Genetics Clinic, where with a team of cancer genetic counselors, we see patients for genetic counseling and testing of hereditary cancer syndromes, and enter patients on clinical research protocols for prevention, early diagnosis and treatment of cancer in high-risk individuals. I have extensive experience in training and mentoring students, fellows and junior faculty members in biomedical sciences and translational research, and many former students and fellows have gone onto faculty positions at prestigious academic centers. I am the Director of the Stanford Oncology Fellowship Training Program and PI of our NCI-supported T32 training grant. In summary, I have a demonstrated record of successful laboratory and translational clinical research, and a track record of mentoring physician-investigators into independent academic careers.

B. Positions and Honors

Professional Positions

1989-91 Intern and Resident, Internal Medicine, Stanford University Medical Center
1991-94 Clinical Fellow, Medical Oncology, Stanford University Medical Center (under Saul Rosenberg, MD)
1993-97 Research Fellow, Dept. of Biological Sciences, Stanford University (with Prof. Phil Hanawalt)
1998-06 Assistant Professor of Medicine (Oncology) and Genetics, Stanford Univ. Medical School
1999- Director, Stanford Cancer Genetics Program and Clinic
2002- Director, Stanford Medical Oncology Fellowship Training Program
2003-06 Assistant Professor of Pediatrics (by courtesy), Division of Medical Genetics
2006- Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics (tenured)
2013- Director, Stanford Clinical Cancer Genomics Program

Other Experience and Professional Activities

2003- California Breast Cancer Research Program (Council Member 03 – 06; 08 – 11; Chair 09 – 10)
2003- V Foundation Scientific Review Committee
2006-13 ASCO Education Committees, Tumor Biology Track Leader (08); Cancer Genetics (11 – 14)
2011-14 ASCO Scientific Program Committee, Tumor Biology Track
2007-08 AACR/NCI/EORTC Annual Meeting Scientific Advisory Board
2003-12 Reviewer, DOD Breast Cancer Research Program, Chair (12)
2002-10 Reviewer, Susan G. Komen Breast Cancer Foundation Research Grant Program (Chair 08 – 10)
2006-07 NIH/NCI Molecular Biology PPG Special Emphasis Panel Study Section

2008-10 NIH/NCI Sub-Committee E – Epidemiology/Prevention Program Project Grant Study Section
2009-13 NIH/NCI Sub-Committee I – Career Development Grant Study Section (Member)
2003- Editorial Boards: *Cancer Research*, *DNA Repair*, *PLoS Genetics*
2005- NCCN Guidelines Committees: Colorectal Cancer Screening; Genetics/Familial High Risk Assessment
2009- Breast Cancer Core Committee, Eastern Cooperative Oncology Group
2010-13 Chair, ASCO Oncology Training Program Directors Subcommittee
2010 - 13 Association of Specialty Professors (ASP) Council
2013 – 16 Member, ASCO Cancer Prevention Committee

Honors and Awards

1984 B.A., *Magna Cum Laude*, Yale University
1995 NIH K08 Clinical Investigator Award
1999 Sidney Kimmel Foundation for Cancer Research Scholar Award
1999 Doris Duke Foundation Clinical Scientist Award in Cancer Etiology and Pathogenesis
2000 Burroughs Wellcome Fund New Investigator Award in Toxicological Sciences
2002 V Foundation Translational Research Award
2005 Evelyn Lauder Breast Cancer Research Foundation Scholar
2007 Member, Western Society for Clinical Investigation
2009-13 Visiting Professorships: Hong Kong Univ. (09); Oxford (09)
2008- Castle Connolly Top Doctor for Cancer
2013- Best Doctors in America – Medical Oncology

C. Selected peer-reviewed publications (Out of a total of 150)

Ford JM, Prozialeck WC, and Hait WN. Structural features that determine activity for phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. *Mol. Pharmacol.* **35:** 105 - 115 (1989).

Ford JM and Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. *Pharmacol. Rev.* **42:**155 (1990).

Ford JM and Hanawalt PC. Li-Fraumeni syndrome human skin fibroblasts homozygous for p53 mutations are deficient in global nucleotide excision repair, but exhibit normal transcription-coupled repair and UV resistance. *Proc. Natl. Acad. Sci.* **92:** 8876-8880 (1995).

Ford JM and Hanawalt PC. Role of DNA excision repair gene defects in the etiology of cancer. *Current Topics in Microbiology and Immunology* **221**:47-70 (1997).

Ford JM and Hanawalt PC. Expression of wild-type p53 is required for efficient nucleotide excision repair in UV-irradiated human fibroblasts. *Journal of Biological Chemistry* **272:** 28073-28080 (1997).

Hwang BJ, **Ford JM**, Hanawalt PC and Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. *Proc. Natl. Acad. Sci., USA* **96:**424-428 (1999).

Tang JY, Hwang BJ, **Ford JM**, Hanawalt PC and Chu G. Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. *Molecular Cell* **5:** 737-744 (2000).

Hartman AR and **Ford JM**. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. *Nature Genetics* **32:**180 – 184 (2002).

Adimoolam S and **Ford JM**. p53 and DNA damage inducible expression of the xeroderma pigmentosum group C gene. *Proc. Natl. Acad. Sci. USA.* **99:** 12985-12990 (2002).

Fitch ME, Cross I and **Ford JM**. p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation induced DNA damage. *Carcinogenesis* **24:** 843 – 850 (2003).

Fitch ME, Cross I, Turner S, Adimoolam S, Lin CX, Williams K, **Ford JM**. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. *DNA Repair* **2:** 819 - 826 (2003).

Fitch ME, Nakajima S, Yasui A and **Ford JM**. *In vivo* stimulation of XPC protein binding to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. *J. Biol. Chem.,* **278:** 46906 – 46910 (2003).

Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, **Ford JM** and Plevritis SK. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. *Cancer*, **100:** 479 – 489 (2004).

Brooks-Wilson AR, **Ford J**, Huntsman D, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. *J. Medical Genetics* **41:** 508 – 517 (2004).

Kurian AW, Mills MM, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, **Ford JM**, AR Hartman. Ductal lavage of fluid-yielding and nonfluid-yielding ducts in BRCA1 and 2 mutation carriers and other women at high inherited breast cancer risk. *Cancer Epidemiol Biomarkers Prev* **14:** 1082 - 1089 (2005).

Suriano G, **Ford JM**, Longacre TA, Norton JA, Chun N, Lynch H, Huntsman DG, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clin Cancer Res* **11:** 5401-5409 (2005).

Bomgarden RD, Lupardus PJ, Yee MC, **Ford JM** and Cimprich KA. Opposing roles of UV lesion repair protein XPA and UV bypass polymerase h on ATR checkpoint activation. *EMBO J*. **7:** 2605 – 2614 (2006).

Chen X, Zhang J, Lee J, Lin P, **Ford JM**, Zheng N and Zhou P. A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. *Mol. Cell.* **22:** 489-499 (2006).

Ji H, Kumm J, Zhang M, Farnam K, Salari K, Faham M, **Ford JM**, Davis RW. Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. *Cancer Research* **66:** 7910-7919 (2006).

Ford JM and Whittemore A. Prediction and prevention of hereditary colorectal cancer. *JAMA* **296**:1521-1523 (2006).

Norton JA, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Kurian AW, Chun N and **Ford JM**. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of Surgery* **245:** 873 – 879 (2007).

Kaurah P, **Ford J**, Pharoah P, Fernandez B, Huntsman D. et al. Founder and recurrent *CDH1* mutations in hereditary diffuse gastric cancer families. *JAMA* **297:** 2360 - 2372 (2007).

Adimoolam S, Sirisawad M, Chen J, Thiemman P, **Ford JM** and Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. **104:** 19482 - 87, *PNAS* (2007).

Kwong A, Wong LP, Chan KYK, Ma ESK, Khoo US and **Ford JM**. Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. *Familial Cancer* **7:** 125-33 (2008).

Staton AD, Kurian AW, Cobb K, Mills MA and **Ford JM**. Risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. *Familial Cancer* **7:** 179-86 (2008).

Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Chun N, Kingham K, **Ford JM** and Longacre TA. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. *American Journal of Surgical Pathology* , **32:** 799 - 809 (2008).

Jensen KC, Mariappan R, Putcha GV, Hussain A, Chun N, **Ford JM,** Schrijver I, and Longacre TA. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. *American Journal of Surgical Pathology* **32:** 1029-37 (2008).

Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BA, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, and **Ford JM**. *BRCA1* and *BRCA2* mutations and predictive model performance in Asian-Americans. *J. Clin. Onc.* **26:** 4752 - 58 (2008).

Alli E, Sharma VB, Sunderesakumar P and **Ford JM**. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. *Cancer Research* **69:** 2589 – 96 (2009).

Lin PS, Chen AY, Sage J and **Ford JM**. The role of the Rb/E2F1 tumor suppressor pathway in nucleotide excision repair. *DNA Repair* **8:** 795-802 (2009).

Kurian AW, McClure LA, John EM, Horn-Ross PL, **Ford JM** and Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. *Journal of the National Cancer Institute* **101:** 1058 – 65 (2009).

Schiffman JD, Wang Y, McPherson LA, Welch K, Zhang N, Davis R, Lacayo NJ, Dahl GV, Faham M**, Ford JM** and Ji H. Molecular inversion probes (MIPs) reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. *Cancer Genetics and Cytogenetics* **193:** 9 – 18 (2009).

Gramatges MM, Telli ML, Balise R and **Ford JM**. Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. *CEBP* **19:** 605-613 (2010).

Telli ML and **JM Ford**. PARP inhibitors in breast cancer. *Clinical Advances in Hem/Onc* **8:** 629 – 635 (2010).

Hastak K, Alli E and **Ford JM**. Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin. . *Cancer Res.* **70:** 7970 – 80 (2010).

Telli ML, Chang ET, Kurian AW, Keegan THM, McClure LA, **Ford JM** and Gomez SL. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast Cancer Res. Treatment* **127:** 471 – 8 (2011).

Schrader KA, **Ford J**, kConFab, Garber JE, Huntsman DG et al. Germline mutations in *CDH1* are infrequent in women with early-onset or familial lobular breast cancers. *J. Med Genetics* **48:** 64 – 68 (2011).

Chen Y, Kingham K, **Ford JM**, Rosing J, Van Dam J, Jeffrey RB, Longacre TA, Chun N, Kurian A and JA Norton. A prospective study of total gastrectomy for *CDH1* positive hereditary diffuse gastric cancer (HDGC). *Annals of Surgical Oncology* **18:** 2594 – 98 (2011).

Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland R, **Ford J**, Elkin E and K Phillips. Strategies to identify the Lynch syndrome among patients diagnosed with colorectal cancer: a cost-effectiveness analysis. *Annals of Internal Medicine* **155:** 69 - 79 (2011).

Alli E, Sharma V, Hartman AR, Lin PS, McPherson L and **Ford JM**. Enhanced sensitivity to cisplatin and gemcitabine in BRCA1-deficient murine mammary epithelial cells. *BMC Pharmacology* **11:** 7 (2011).

Nadauld LD and **JM Ford**. Family history as a positive prognostic factor in gastric cancer. *J. Clinical Oncology* (2012).

Alli E and **JM Ford**. Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. *DNA Repair,* **11:** 522 - 4 (2012).

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick J, Sheth S, Kurian AW, **Ford JM**, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, G Bhanot, Dairkee SH, Davis RW and SS Jeffrey. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. *PLoS One* 7:1-11 (2012).

Masciari S, Dillon DA, Rath M, Robson M, Weitzel JM, Balmana J, Gruber SB, **Ford JM**, Euhus D, Lebensohn A, Telli M, Lypas G and JE Garber. Breast cancer phenotype in women with *TP53* germline mutations: a Li-Fraumeni Syndrome consortium effort. *Breast Cancer Res. Treatment*, **133:** 1125 – 30 (2012).

Ji HP, Morales S, Welch K, Yuen C, Farnham K and **JM Ford**. Identification of a novel deletion mutant strain in *Saccharomyces cerevisiae* that results in a microsatellite instability phenotype. *BioDiscovery* **1:** 1 – 9 (2012).

Chun N and **Ford JM**. Genetic testing by cancer site: stomach. *Cancer Journal* **18**: 355 - 63 (2012).

Ford JM. Is breast cancer a part of Lynch syndrome? *Breast Cancer Res.* **14:** 110 (2012).

De Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, **Ford JM**, and AW Kurian. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. *Familial Cancer,* Epub ahead of print (May 26, 2012).

Hastak K, Adimoolam S, Trinklein ND, Myers RM and **JM Ford.** Identification of a functional in vivo p53 response element in the coding sequence of the xeroderma pigmentosum group C gene. *Genes & Cancer* **3:** 131 – 40 (2012).

Kunz PL, Gubens MN, Fisher GA, **Ford JM**, Lichtensztajn D, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. *J. Clinical Oncology* **30:** 3507 - 3515 (2012).

Ladabaum U and **Ford JM**. Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. *JAMA* **308:** 1581 – 1583 (2012).

Ford JM. Focus: Lupus antibody tops cancer cells. *Sci. Transl. Med.* **4:** 132fs38 (2012).

Nadauld L, Regan J, Miotke L, Pai R, Longacre T, Kwok S, Saxonav S, **Ford JM** and H Ji. Quantitative and sensitive detection of cancer genome amplifications from formalin fixed paraffin embedded tumors with droplet digital PCR. *Translational Medicine Medicine* **2:** 107 (2012).

Nadauld LD and **JM Ford**. Molecular profiling of gastric cancer: toward personalized cancer medicine. *J. Clin. Oncology* **31:** 838 - 9 (2013).

Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton AS, Mills MA, Schackmann EA, Telli ML, Kardashian A, **Ford JM**, and AW Kurian. A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. *Breast Cancer Research and Treatment* **142:**389-98 (2013).

McPherson LA, Shen Y and **JM Ford.** Poly (ADP-ribose) Polymerase inhibitor LT-626: Sensitivity correlates with *MRE11* mutations and synergizes with platinums and irinotecan in colorectal cancer cells. *Cancer Letters* **343:** 217 – 223 (2014).

Lu K, Wood M, Daniels M, Burke C, **Ford J**, Kauff N, Kohlman W, Lindor N, Mulvey T, Robinson L, Rubinstein W, Stoffel E, Snyder C, Syngal S, Merrill J, Wollins DS and K Hughes. ASCO expert statement: collection & utilization of a cancer family history. *J. Clin. Oncology* Epub ahead of print (Nov 12, 2013).

Burt RW, Cannon JA, David DS, Early DS, **Ford JM**, Giardiello FM, Halverson AL, Hamilton SR, Hampel H, Ismail MK, Jasperson K, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Ness RM, Provenzale D, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Dwyer M and D Freedman-Cass. Colorectal Cancer Screening. *J Natl Compr Canc Netw.* **11:**1538-75 (2013).

Kurian AW, Hare E, Mills MM, Kingham KE, McPherson L, Whittemore AS, McGuire V, Gong G, Ladabaum U, Kobayashi Y, Cargill M and **JM Ford**. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. In Press, *J Clin Oncology* (2014).

Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein J, Chaib H, Goldfeder RL, Ormond KE, Caleshu C, Kingham K, Klein TE, Whirl-Carillo M, Sakamoto K, Wheeler MT, Butte AJ, Merker J, **Ford J**, Boxer L, Ioannidis JPA, Yeung AC, Altman RA, Assimes TL, Snyder M, Ashley E and T Quertermous. Opportunity and cost of clinical whole genome sequencing. In Press, *JAMA* (2014).

Ongoing Research Support

Breast Cancer Research Foundation (Ford, PI) 10/01/05 – 9/30/14

Genetics and Clinical Research in Breast Cancer.

(1). Lovastatin for Breast Cancer Chemoprevention and Biomarker Modification
(2). Targeting DNA Repair Defects in Triple-Negative Breast Cancer
(3). Improving Breast Cancer Genetic Risk Assessment

NIH/NCI 5T32 CA009287-32 (Ford, PI) 7/08/09 – 6/30/14

Training Program in Investigative Oncology.

To train oncology fellows in basic laboratory, translational and clinical research.

NIH/NCI 1U54 CA136465-01 (Contag, PI) 9/01/09 – 8/31/13
Multimodality Imaging of GI Cancers for Diagnosis and Directed Therapy
This network grant aims to advance molecular probes and therapies to better diagnosis and treat cancers of the gastrointestinal tract with image guidance.

BiPar Sciences, Inc. (Ford and Telli, Co-PI's) 1/22/09 – 1/21/13
A phase II study of gemcitabine, carboplatin and poly(ADP-ribose) polymerase (PARP) inhibitor BSI-201 in the neoadjuvant treatment of triple-negative breast cancer.

Varian Associates (Ford, PI) 1/31/11 - 7/30/13
Assessing the Radiosensitizing Effects of PARP Inhibitors in Pancreatic Cancer using Different Dose-Fractionation Schemes

Stanford Cancer Institute Interactive Dev. Research Award (Ford, PI) 9/1/11 – 8/31/13
An integrated approach to gastric cancer pathogenesis and therapy

Stanford Cancer Institute PopSci Dev. Research Award (Ford, Co-PI) 9/1/11 – 8/31/13
Can Emerging Genetic Tests Improve Breast Cancer Risk Assessment?

FasterCures (Ford, PI) 12/1/11 – 11/30/13
Colorectal Cancer Research Acceleration Award
The overall objective is to advance the development of new therapies for late-stage, metastatic colorectal cancer with wild-type KRAS.

Genentech (Ford, PI) 11/09/12 – 11/30/14
A Randomized, multicenter, adaptive
Phase II/III study to evaluate the efficacy and safety of T-DM1 versus Taxane in patients with previously treated locally advanced or metastatic HER2-Positive Gastric Cancer.

Astra Zeneca (Ford, PI) 3/07/2013 - 2/28/2018
A phase I, open label, multcentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD4547 in patients with advanced solid malignancies.

Completed Research Support

NIH/NCI 1R21 NS061674-01A2 (Ford, PI) 06/01/10 – 5/30/12
A High-Throughput Assay for DNA Repair Activity in the Presence of Aberrant BRCA1.
To screen large compound libraries for small molecules that activate base-excision DNA repair.

Stanford Univ. Cancer Center Developmental Research Award (Telli, PI) 9/1/10 – 8/31/11
Identifying molecular determinants of response to PARP inhibition in early stage triple-negative breast cancer.
To assess molecular determinants of response, including gene copy number alterations, among triple-negative breast cancer patients treated with neoadjuvant gemcitabine, carboplatin and the PARP inhibitor BSI-201.

Triple Negative Breast Cancer Foundation 3/03/11 - 2/28/11
Determinants of Drug Resistance to PARP Inhibitors in Triple Negative Breast Cancer

Komen Postdoctoral Fellowship – Basic Research (Ford, PI) 7/08/08/08 – 7/07/11
BRCA1-mediated Regulation of Oxidative DNA Damage in Breast Cancer (Alli)

Komen Postdoctoral Fellowship – Basic Research (Ford, PI) 7/16/08/08 – 7/15/11
Genetic Determinants of Chemosensitivity in Triple Negative Breast Cancer Cells (Hastak)

NIH/NCI R03 (West, PI) 7/01/08 - 6/30/10
Study of Genetic Mutation Carriage in Chinese Populations with Breast Cancer

Center for Children's Brain Tumors at LPCH (Ford, PI) 7/01/08 - 6/30/10
Novel Genomic Technology to Classify and Risk Stratify Pediatric Gliomas

NIH/NCI 1R01 CA108794-01 (Ford, PI) 7/01/04 – 6/30/09
Ubiquitin-Mediated Regulation of DNA Repair.

Mary Kay Ash Charitable Foundation (Ford, PI) 7/01/07 - 6/30/09
A Novel Approach to Identify Chemoprevention Agents for BRCA1-Associated Malignancies.

NIH/NCI R21 CA109190-01 (Ford, PI) 4/01/05 - 4/30/08
Genome-Wide Allelic Imbalances in Colon Cancer

The Susan G. Komen Breast Cancer Foundation POP0503911 (Ford, PI) 5/1/05 - 4/30/08
A Clinic-Based Study of BRCA Mutation Carriage, Differences in
BRCAPRO Scores, and Breast Risk Factors Among Asians and Caucasians.

DOD Idea Award (Ford, PI) 5/07/04 - 5/06/07
Loss of Nucleotide Excision Repair as a Source of Genomic Instability in Breast Cancer

V Foundation Translational Research Grant (Ford, Co-PI) 10/1/02 – 10/1/05
Determinants of Genomic Instability in Women
with BRCA1 Mutations undergoing Comprehensive Breast Cancer Screening.

Clinical Research Scientist Award (Ford, PI) 7/02/99 - 6/30/04
Doris Duke Charitable Foundation
Molecular Basis of Drug Sensitivity in Upper GI Cancers

Burroughs Wellcome Fund New Investigator Award (Ford, PI) 7/01/00-06/20/03
Transcriptional Regulation of DNA Damage Inducible DNA Repair Genes

NIH/NCI RO1 CA83889-03 (Ford, PI) 1/01/00-12/31/03
Mechanism of p53-Dependent DNA Excision Repair

Sidney Kimmel Foundation Scholar Award (Ford, PI) 7/01/99 - 6/30/01
Mechanism of p53 - Dependent DNA Repair

NIH/NCI K08 Clinical-Investigator Award (Ford, PI) 9/01/95 – 8/30/99
Role of p53 gene in cellular sensitivity to DNA damage